On December 20, 2024, Zonhonbio's Class 1 innovative biological drug, ZHB015 for Injection, has received the "Clinical Trial Approval Notice" from China's National Medical Products Administration (NMPA). ZHB015 for injection is an original research and development by Zonhonbio, with completely independent intellectual property rights both domestically and internationally. It is a bispecific antibody drug developed using innovative targets and has been approved for use in advanced malignant solid tumors.